MET MET proto-oncogene, receptor tyrosine kinase
ENSG00000105976 · protein coding · Open Targets profile
Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces autophosphorylation of MET on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. The RAS-ERK activation is associated with the morphogenetic effects while PI3K/AKT coordinates prosurvival effects. During embryonic development, MET signaling plays a role in gastrulation, development and migration of neuronal precursors, angiogenesis and kidney formation. During skeletal muscle development, it is crucial for the migration of muscle progenitor cells and for the proliferation of secondary myoblasts (By similarity). In adults, participates in wound healing as well as organ regeneration and tissue remodeling. Also promotes differentiation and proliferation of hematopoietic cells. May regulate cortical bone osteogenesis (By similarity). .
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- Approved Drug, Structure with Ligand, High-Quality Ligand, High-Quality Pocket, Druggable Family
- Antibody
- Approved Drug, GO CC high conf, UniProt loc med conf, UniProt SigP or TMHMM, Human Protein Atlas loc
- PROTAC
- Literature, UniProt Ubiquitination, Database Ubiquitination, Half-life Data, Small Molecule Binder
- Other modalities
- Advanced Clinical
gnomAD loss of function constraint: o/e 0.36059999465942383 (upper bound 0.4586699903011322). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 367 registry trials, updated in the last three years, of the most advanced drugs against MET (tepotinib, cabozantinib s-malate, capmatinib, crizotinib, amivantamab, cabozantinib, savolitinib, telisotuzumab vedotin, onartuzumab, beperminogene perplasmid, tivantinib, terevalefim), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Shun LuShanghai Chest Hospital · 4 of 4 trials Phase 2+
- Yongchang ZhangHunan Cancer Hospital · 3 of 3 trials Phase 2+
- Farshid DayyaniChao Family Comprehensive Cancer Center · 2 of 3 trials Phase 2+
- Antoine ItalianoInstitut Bergonie Cancer Center · 2 of 2 trials Phase 2+
- Bhavana KondaAlliance for Clinical Trials in Oncology · 2 of 2 trials Phase 2+
- Caicun ZhouShanghai East Hospital · 2 of 2 trials Phase 2+
- David S HongECOG-ACRIN Cancer Research Group · 2 of 2 trials Phase 2+
- Joel W NealECOG-ACRIN Cancer Research Group · 2 of 2 trials Phase 2+
- Matthew KrebsThe Christie Hospital · 2 of 2 trials Phase 2+
- Salah-Eddin Al-BatranInstitut für Klinische Krebsforschung IKF GmbH · 2 of 2 trials Phase 2+
- Tian ZhangAlliance for Clinical Trials in Oncology · 2 of 2 trials Phase 2+
- Andrea B ApoloAlliance for Clinical Trials in Oncology · 1 of 2 trials Phase 2+
- Sumanta K PalCity of Hope Medical Center · 1 of 2 trials Phase 2+
- Umang SwamiHuntsman Cancer Institute · 1 of 2 trials Phase 2+
- A P ChenNational Cancer Institute LAO · 1 of 1 trials Phase 2+
Registry trials of tepotinib, cabozantinib s-malate, capmatinib, crizotinib, amivantamab, cabozantinib, savolitinib, telisotuzumab vedotin, onartuzumab, beperminogene perplasmid, tivantinib, terevalefim updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 226 of 355 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 12 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.
99 trials of drugs against MET were stopped early; 14 give no reason
Terminated, withdrawn and suspended interventional trials of tepotinib, cabozantinib s-malate, capmatinib, crizotinib, amivantamab, cabozantinib, savolitinib, telisotuzumab vedotin, onartuzumab, beperminogene perplasmid, tivantinib, terevalefim, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 25 most recent of 99.
- suspended · 2026-11-02 · National Cancer Institute (NCI) · Cabozantinib S-malate“Scheduled Interim Monitoring”
- terminated · 2026-10-29 · Ipsen · Cabozantinib“The sponsor has decided to terminate the CabOSTar study due to ongoing recruitment challenges”
- suspended · 2026-10-27 · National Cancer Institute (NCI) · Cabozantinib S-malate“Other - Extend the observation period for current patients”
- suspended · 2026-06-05 · Megan Kruse, MD · matched by the registry's drug synonyms“Anheart acquired by Nuvation Bio; leadership not moving forward”
- terminated · 2026-05-01 · Weill Medical College of Cornell University · Cabozantinib“Low accrual”
- terminated · 2026-04-23 · National Cancer Institute (NCI) · Crizotinib“Inadequate accrual rate”
- terminated · 2026-03-19 · Hoffmann-La Roche · Cabozantinib“As the study did not meet it's primary endpoint a decision was made to terminate the study.”
- terminated · 2026-02-25 · Exelixis · Cabozantinib“Enrollment in this study was terminated for business development reasons before completing one third of the expected subject population, no formal statistical testing was performed.”
- withdrawn · 2026-02-17 · University of Alabama at Birmingham · matched by the registry's drug synonyms“due to overall cost of the study”
- terminated · 2026-02-09 · Genenta Science · Cabozantinib“Persistent challenges have been encountered in patient recruitment, difficulty in identifying a sufficient number of eligible subjects. The decision to terminate the study was not based on any safety concerns. Benefit-risk profile of IP unchanged.”
- terminated · 2026-01-29 · John Rieth · Cabozantinib“Study was terminated early due to changes in the treatment of melanoma”
- terminated · 2026-01-08 · Exelixis · cabozantinib“Sponsor decided to close the study prior to completion of enrollment. This was a business decision and not based on the safety results of the study.”
- terminated · 2025-10-24 · AbbVie · Telisotuzumab Vedotin“Strategic considerations”
- terminated · 2025-10-16 · Novartis Pharmaceuticals · capmatinib“The study was terminated early due to recruitment challenges.”
- terminated · 2025-07-17 · University of Washington · Cabozantinib S-malate“Terminated due to end of funding”
- terminated · 2025-07-16 · National Cheng-Kung University Hospital · Crizotinib 250 MG“Patients were recruited during screen phase but fewer patients met criteria.”
- terminated · 2025-06-11 · M.D. Anderson Cancer Center · Capmatinib“Sponsor Withdrew Support”
- terminated · 2025-05-18 · Novartis Pharmaceuticals · capmatinib“This was a sponsor decision and was not a consequence of any safety concern”
- terminated · 2025-05-16 · Novartis Pharmaceuticals · Capmatinib“Company decision not related to any safety concerns.”
- terminated · 2025-02-10 · Blueprint Medicines Corporation · matched by the registry's drug synonyms“Sponsor decision, not related to safety concerns”
- terminated · 2025-01-23 · Pfizer · Crizotinib“Termination of further treatment on the study due to the availability of commercial supply or a rollover study (NCT05160922) that will allow active subjects to continue receiving treatment.”
- terminated · 2025-01-13 · Janssen Research & Development, LLC · Amivantamab“N\~15 subjects data analysis did not meet statistical consideration of ORR and study primary/secondary objectives were not met. Enrollment was terminated for futility”
- terminated · 2024-11-08 · Pfizer · Crizotinib“The trial is terminated based on business decision, not due to safety concerns or regulatory requirements.”
- terminated · 2024-10-09 · Novartis Pharmaceuticals · Capmatinib“Sponsor decision to terminate due to the lack of tolerability observed in patients treated with capmatinib and pembrolizumab in the combination arm as compared to patients treated with pembrolizumab alone in the pembrolizumab single agent arm”
- terminated · 2024-10-09 · Novartis Pharmaceuticals · Capmatinib“Study termination based on sponsor decision due to lack of tolerability observed with capmatinib and spartalizumab combination treatment when compared to data from capmatinib single agent studies”
Paediatric incentives and obligations for MET's drugs
For tepotinib, cabozantinib s-malate, capmatinib, crizotinib, amivantamab, cabozantinib, savolitinib, telisotuzumab vedotin, onartuzumab, beperminogene perplasmid, tivantinib, terevalefim: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: yes · MET is on the list. Membership alone neither requires nor waives a pediatric study.Rule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: yes · EMEA-002573-PIP02-23 (amivantamab, Treatment of colorectal carcinoma): W: decision granting a waiver in all age groups for all conditions or indications, 6 May 2024; EMEA-001143-PIP01-11-M06 (cabozantinib, Treatment of solid malignant tumours): PM: decision on the application for modification of an agreed PIP, 7 Aug 2023; EMEA-001493-PIP03-18-M01 (crizotinib, Treatment of anaplastic large cell lymphoma;Treatment of inflammatory myofibroblastic tumours): PM: decision on the application for modification of an agreed PIP, 27 Jan 2021; compliance positive 31 Mar 2023; EMEA-002627-PIP02-21 (savolitinib, Treatment of renal neoplasms): W: decision granting a waiver in all age groups for all conditions or indications, 8 Jun 2021; +6 moreRule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
- EU orphan designation: yes · EU/3/08/610 positive 6 Feb 2009: Treatment of medullary thyroid carcinoma; - negative 28 Jun 2021: Treatment of partial deep dermal and full-thickness burns; EU/3/13/1202 withdrawn 13 Nov 2013: Treatment of hepatocellular carcinomaRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: yes · Cabometyx: authorised since 9 Sept 2016; Cometriq: authorised since 21 Mar 2014, orphan medicine; Tepmetko: authorised since 16 Feb 2022; Xalkori: authorised since 23 Oct 2012; +2 moreRule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: yes · Crizotinib [Xalkori], 14 Jul 2022: Treatment of adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive; Crizotinib [Xalkori], 14 Jan 2021: Treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive; Cabozantinib [Cabometyx], 26 Mar 2025: Treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic neuroendocrine tumors (epNET); +2 moreRule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-11
- Registered studies open to children: yes · 56 interventional studies of tepotinib, cabozantinib s-malate, capmatinib, crizotinib, amivantamab, cabozantinib, savolitinib, telisotuzumab vedotin, onartuzumab, beperminogene perplasmid, tivantinib, terevalefim include patients under 18; 21 are recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-11
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 38 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.